Drug Profile
Bamlanivimab - Abcellera/Eli Lilly and Company
Alternative Names: LY 3819253; LY CoV 555Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Abcellera; Eli Lilly and Company
- Developer Abcellera; Eli Lilly and Company; National Institute of Allergy and Infectious Diseases
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 10 Oct 2023 9399857 - Financing info added
- 04 Aug 2023 Phase-III clinical trials in COVID-2019 infections (Combination therapy) in Nigeria (IV) (NCT04501978) (EudraCT2020-003278-37)
- 14 Jul 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes a phase-III trial in COVID-2019 infections (Combination therapy) in Singapore, Denmark, Spain, Switzerland, Nigeria, Greece, United Kingdom, USA, Uganad, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)